{content}

Study list

Vicente-Valor

Spain
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

LC-cohort

Finland
|
2021-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

LCV

Italy
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post-COVID-19

Huygens

The Netherlands
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

POSTCODE

United Kingdom
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

BronchSTART

United Kingdom Ireland
|
2021-2026
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Azevedo

Portugal
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19

MEADOWSPRING

Argentina Belgium Brazil Denmark Germany Mexico Romania Switzerland Turkiye Ukraine
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

Peghetti

Italy
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

BRAINSTORM

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post-COVID-19

Lindsay

United Kingdom
|
2021
  • Adults (18-64 years)
  • Fragile population
  • SARS-CoV-2
  • Post-COVID-19

Post-Covid UKF

Germany
|
2021
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

SubFSC19-KN

Germany
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

LUNGTERMcov

Switzerland
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19

COMEBAC 2

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post-COVID-19

Ballmann

Germany
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Post-COVID-19

Hedman

Sweden
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

Steinmetz

Germany
|
2021
  • General population
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

COVIMMUNE-Clin

Germany
|
2021
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19

D’Hondt

Belgium
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

PCS_Fettoxidation

Germany
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

Weidlich

Germany
|
2021-2022
  • Adults (18-64 years)
  • People at high risk of STIs
  • Men who have sex with men
  • Non-hospital health centre
  • STD/STI clinic
  • Chlamydia trachomatis
  • Neisseria gonorrhoeae
  • Sexually transmitted infection
  • Non pharmacological intervention
  • RT-PCR

DisCOVID

France
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post-COVID-19

ERiDenF

France
|
2021-2023
  • Pregnant women
  • Hospital
  • Arbovirus
  • Dengue virus
  • Vector-borne disease
  • Arboviral disease
  • Vector-borne disease